Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + nab-paclitaxel + atezolizumab + nogapendekin alfa inbakicept
- Development stage
- Discontinued
- Lead developer
- ImmunityBio
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Subcutaneous
01
Overview
carboplatin + nab-paclitaxel + atezolizumab + nogapendekin alfa inbakicept is a combination chemo-immunotherapy regimen developed by ImmunityBio for the first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). This four-drug regimen integrates standard-of-care cytotoxic chemotherapy (carboplatin and nab-paclitaxel) with the PD-L1-targeting monoclonal antibody atezolizumab and the IL-15 receptor agonist superagonist nogapendekin alfa inbakicept (NAI, also known as N-803 or Anktiva). The mechanism of action involves carboplatin-induced DNA cross-linking and nab-paclitaxel-mediated microtubule stabilization to inhibit tumor cell division, while atezolizumab blocks the PD-1/PD-L1 checkpoint to restore T-cell activity. Nogapendekin alfa inbakicept further enhances the immune response by specifically stimulating the proliferation and activation of natural killer (NK) cells and CD8+ T cells without inducing regulatory T cell expansion. This combination is being evaluated in the Phase 3 QUILT-2.023 clinical trial.
- Other names
- NAInogapendekin alfa inbakicept-pmln
02
Targets
IL2RB (IL-2 receptor beta chain)CD274 (Programmed cell death protein 1 ligand 1)DNAIL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on carboplatin + nab-paclitaxel + atezolizumab + nogapendekin alfa inbakicept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + nab-paclitaxel + atezolizumab + nogapendekin alfa inbakicept.